In support of this, pharmacological inhibition of another key enzyme in the fatty acid synthesis pathway, FASN (Fatty Acid Synthase), enhanced the effects of bortezomib in prostate cancer cells [42]. The gene discussed is FASN; the disease is prostate carcinoma.